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Abstract: This work aimed to investigate the feasibility to design: (a) a mucoadhesive
interpolyelectrolyte complex (IPEC) loaded with clobetasol propionate (CP) intended to treat oral
lichen planus and (b) individuate an orodispersible dosage form suitable for its administration.
IPECs were synthesized by mixing Eudragit® E PO (EPO) and different grades of cross-linked
polyacrylate derivatives, in different molar ratios, namely 1:1, 1:2, and 2:1. All IPECs resulted at
nanoscale independently of their composition (120–200 nm). Both zeta-potentials (ζ) and mucoadhesive
performances were influenced by the ratio between polymers. On the bases of the preliminary data,
IPECs made of Polycarbophil and EPO in the 1:2 ratio were loaded with CP. The encapsulation
efficiency was up 88% independently of the CP-IPEC ratio. The drug encapsulation caused IPEC
destabilization in water, as it was noticed by the increase of ζ values and the formation of aggregates.
Oral lyophilisates were prepared by freeze-drying slurries made of placebo or CP loaded IPECs,
maltodextrin with a dextrose equivalent 38 and Span®80. The optimized formulation permitted to
obtain a fast disintegration upon contact with water reducing the tendency of IPECs to aggregate.
Moreover, oral lyophilisates allowed improving the apparent solubility of CP throughout the in vitro
release experiment.
Keywords: Carbopol; clobetasol; Eudragit® E PO; interpolyelectrolyte complex; mucoadhesion;
oral lichen planus; oral lyophilisates; maltodextrin; resuspendibility
1. Introduction
Interpolyelectrolyte complexes (IPECs) are formed in aqueous dispersions by spontaneous
association of oppositely charged polyelectrolytes due to strong but reversible electrostatic
interactions [1]. The mild preparation procedure and responsiveness to various stimuli (i.e., pH,
temperature, and osmolarity) without cross-linking agents or auxiliary molecules, e.g., catalysts,
thereby reducing possible toxicity and other undesirable effects of the reagents. As the obtained
polymeric networks are biocompatible and well-tolerated, they are exploited in drug delivery to
administer both small drugs [2] and peptides or proteins by several routes, e.g., ocular [3], nasal [4],
and oral [5].
Depending on the main features of selected polymers, IPECs exhibit peculiar physico-chemical
properties due to their electrostatic interactions and flexibility. For instance, upon mixing two aqueous
solutions of oppositely charged polyelectrolytes in a stoichiometric ratio, the resulting IPEC is insoluble
and precipitates out [6], often as a colloid [7]. Then, the definition of a suitable drying technique, and
the relative protocol, is required to improve their physical and microbiological stability. However,
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drying could also cause the formation of irreversible aggregates of irregular shape and size considering
the IPEC dimensions.
Recently, a type of IPEC constituted by a poly(amino methacrylate) and an anionic polyacrylate
derivative was proposed as mucoadhesive microparticles [8] which could be exploited in the treatment
of buccal pathologies since it prolongs the residence time on a wide surface area. In contrast, the design
of a suitable dosage form to administer a powder in the buccal cavity could be problematic in terms
of dose accuracy and the easiness in handling. In the attempt to solve these issues, in this work we
demonstrated the feasibility to prepare oral lyophilisates [9] containing mucoadhesive IPEC composed
of Eudragit® E PO (EPO) and Polycarbophil®. This material was chosen among a homogenous series of
cross-linked polyacrylate derivatives able to provide the original suspension with unmodified particle
size and size distribution, as detailed in Scheme 1. IPECs were loaded with Clobetasol proprionate
(CP) selected as a model drug since it is mainstay of topical treatment for oral lichen planus (OLP) [10].
It should be noted that despite many international guidelines refer that its topical application allows
good management of this condition reducing systemic side-effects [11], dosage forms intended for
buccal route are still not available.
The experimental work was organized in three steps, as detailed in Scheme 1, which
summarizesthe the selection criteria and the most important variables to be considered. Firstly, placebo
IPECs made of EPO and four different types of carbomers were produced to elucidate the effect of the
polycomplex composition on mucoadhesive properties and physico-chemical features. IPECs with
satisfactory mucoadhesive properties were loaded with different amounts of CP to investigate the
maximum loading ability of IPECs. Secondly, placebo and CP loaded IPECs were formulated as
oral lyophisates using maltodextrin as main matrix forming materials due to its excellent water
solubility [12]. Finally, considering the low aqueous solubility of CP (~4 mg/mL) [13], the possibility
to improve the drug apparent solubility was also investigated.
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2. Materials and Methods
2.1. aterials
Eudragit E PO (EPO) a terpoly er of N,N-di ethyla inoethyl ethacrylate (D AE A)
ith methylmethacrylate (M A) and butylmethacrylate (BuMA), (PDMAEMA–co–MMA–co–BuMA)
(mole ratio 2:1:1, MW 150 kDa) was used in this study as a cationic copolymer. Different grades
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of carbomer derivatives (Carbopol® 71G NF polymer (C71G), Carbopol® ETD 2020 NF polymer
(C2020), Carbopol® Ultrez 10 NF polymer (C10) and Noveon® AA-1 Polycarbophil USP (NAA-1))
were used as polyanions. EPO and different types of Carbopol® (C71G, C2020, C10) as well as
Noveon® AA-1 (NAA-1) were generously donated by Evonik Röhm GmbH (Darmstadt, Germany) and
Lubrizol Advanced Materials (Wickliffe, OH, USA), respectively. Their main relevant physicochemical
characteristics as specified by manufacturers are summarized in Table 1. The polymers were used
after drying at 40 ◦C under vacuum over a 2 day-period. Maltodextrin with a dextrose equivalent
38 (Glucidex IT38, DS) was kindly gifted by Roquette (Lestrem, France). Span®80 and Tween®80
were provided by Croda Lubricants (Snaith, UK) and Carlo Erba Reagenti, (Milan, Italy), respectively.
Clobetasol 17-propionate (CP) was purchased from SICOR (Pero, Italy). All solvents were of analytical
grade, unless specified.
Table 1. Physicochemical characteristics as specified by Evonik (healthcare.evonik.com) for Eudragit®
E PO (EPO) and Lubrizol Advanced Materials (lubrizol.com) for polycarbophil and different
grades of carbomer used to prepare interpolyelectrolyte complex (IPEC). (Abbreviation: Monomers:
AA—acrylic acid; EG—ethylene glycol; PAA—polyacrylic acid; crosslinking agents: AEPE—allyl ester
of pentaerythritol; DVG—divinyl glycol).
Grade (Code) Type of Polymer Viscosity (0.5%,pH 7.5), cP MW (kDa)
Mesh Size—Distance
between Crosslinks
(kDa)
ζ (mV)
C2020
Carbomer interpolymer. Type B
(copolymer of AA and EG
crosslinked with AEPE)
47,000–77,000 4500 11.4 −36.2 ± 2.7
C71G Carbomer homopolymer. Type A(PAA, crosslinked with AEPE) 4000–11,000 3000 237.6 −51.0 ± 2.0
C10 *
Carbomer interpolymer. Type A
(block copolymer of EG and a
long chain alkyl acid ester)
45,000–65,000 3000 - * −33.3 ± 2.1
NAA-1 * Polycarbophil(PAA, crosslinked with DVG) 2000–12,000 3000 - * −40.1 ± 2.1
EPO Butylated methacrylatecopolymer - 150 - 45.7 ± 2.1
* No data available.
2.2. Synthesis of Placebo and CP Loaded IPECs
The conditions to optimize the interaction between chemically complementary grades of a
polycationic (EPO) and a polyanionic (C71G, C2020, C10, NAA-1) polymer in the presence of CP were
evaluated in an aqueous medium. EPO solution was obtained dissolving EPO in 1 M CH3COOH. Then,
it was diluted with deionized water to the required volume and the pH was adjusted to 7.0 with 1 M
NaOH. Carbomer dispersions were prepared by dispersing and swelling the polymer in 1 M NaOH.
This dispersion was diluted with demineralized water to the desired volume and the pH was adjusted
to 7.0 with 1 M CH3COOH. The EPO solutions were slowly poured into carbomer-CP dispersions [10].
The solutions and dispersions of copolymers and CP were mixed in different IPEC-CP weight ratios
(e.g., 90:10, 80:20, 70:30, 60:40, 50:50 w/w), using three Carbomer/EPO ratios in synthesized IPECs
(in equal quantities and with an excess of EPO or Carbopol®).
The optimal composition of IPEC (placebo) and IPEC-CP systems were obtained in a reactor
system LR 1000 control equipped with pH- and temperature controlling units (IKA®, Staufen, Germany)
under continuous agitation using overhead stirrer Eurostar 60 control (IKA®, Staufen, Germany) at
500 rpm. The feeding rate of EPO solution was about 2 mL/min and mixtures were stirred over a
7 day period. After the isolation, IPEC-CP particles were washed with ultrapure water (Smart2Pure
UV/UF, Thermo Fisher Scientific, Waltham, MA, USA) and subsequently dried under vacuum at 40 ◦C
(vacuum oven VD 23, Binder, Germany) over a 2 day period until constant weight. The samples were
stored in tightly sealed containers at room temperature until use. The elementary analysis on placebo
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IPEC samples was carried out by a Thermo Flash 2000 CHNS/O elemental analyzer (Thermo Fisher
Scientific, Paisley, UK).
2.3. IPEC Characterization
2.3.1. Dynamic Light Scattering
To determine the hydrodynamic diameter (Dh) of IPECs, laser diffraction analysis was carried out
using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK). This technology determines
particle sizes in the range from 0.5 nm to 5 µm allowing the detection of particle aggregates in a
suspension. Since the particle stability was not sufficient in pure water during a single measurement,
Span®80 at the concentration of 0.25% was used as a steric stabilizer. The analysis was conducted at a
scattering angle of 173◦ and a temperature of 25 ◦C.
2.3.2. Zeta-Potential Measurements
Charge was determined as the zeta potential (ζ) by using folded capillary cell at 25 ◦C
using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK). The results are reported
as mean ± standard deviation (n = 3).
2.3.3. Modulated DSC Analysis
Thermal analysis on IPEC, CP, IPEC-CP were carried out using a modulated differential scanning
calorimetry (MDSC; Discovery DSC™, TA Instruments, Newcaste, DE, USA), equipped with a
refrigerated cooling system (RCS90, TA Instruments, Newcastle, DE, USA). Samples of about 5 mg
exactly weighted were sealed in Tzero aluminium pans (TA Instruments, Newcastle, DE, USA) and
empty pan was used as a reference. The mass of the reference and sample pans were considered
to normalize the data. Dry nitrogen at a flow rate of 50 mL/min was used to purge the DSC cell.
Indium and n-octadecane standards were used to calibrate the DSC temperature scale; enthalpic
response and heat capacity were calibrated with indium and sapphire, respectively. The modulation
parameters were set as follows: 2 ◦C/min heating rate, 40 s period and 1 ◦C amplitude. Samples were
analyzed from 25 to 250 ◦C. Glass transition temperature was determined in the reversing heat flow
signals by using TRIOS™ software (version 3.1.5.3696, TA Instruments, Newcastle, DE, USA).
2.3.4. FTIR-Spectroscopy
ATR-FTIR-spectra were recorded using a Nicolet iS5 FTIR-spectrometer (Thermo Fisher Scientific,
Waltham, MA, USA) equipped with a DTGS detector (Thermo Fisher Scientific, Waltham, MA, USA).
IPECs, raw polymers (i.e., C71G, C2020, C10, NAA-1) and vacuum-dried IPEC-CP were directly placed
on the iD5 smart single bounce ZnSe ATR crystal. The spectra were analysed using OMNIC spectra
software (Thermo Fisher Scientific, Waltham, MA, USA).
2.4. In Vitro Mucoadhesive Properties of Placebo IPECs
The texture analysis was performed as previously described [14] using mucin as the adherent
substrate [15]. Mucoadhesive properties were determined by using a software-controlled texture
analyzer (Instron 5965, Instron, Pianezza, Italy) equipped with a 50 N force cell in adhesion mode.
A flat faced compact of testing materials (weight: 170 mg, diameter: 11.28 mm) was obtained by
applying a compression force of 10 tons for 30 s by means of a hydraulic press (Glenrothes, UK).
Compacts were glued to the mobile steel punch. A mucin compact (weight: 130 mg, diameter:
11.28 mm) obtained applying a compression force of 10 tons for 60 s, was glued to a steel plate fixed
at the bottom of the tensile apparatus. Both compacts were hydrated with 50 µL deionized water for
5 min to obtain a jelly layer. Upon making contact between the two hydrated compacts, a constant
force of 1.3 N was applied over 360 s. The mucoadhesive properties were expressed as maximum
detachment force (MDF), namely the force required to separate the IPEC compact from mucin upon
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an elongation of 25 mm at the rate of 0.1 mm/s; work of adhesion (WA), namely the area under the
curve of the detachment force versus the elongation which represents the energy necessary to detach
two compacts. Polyethylene plates and chitosan compacts were used as negative and positive control,
respectively. The results are expressed as mean ± standard deviation (n = 4).
2.5. Preparation of Oral Lyophilisates
To set-up the freeze-drying parameters, the glass transition temperature of the maximally
freeze-concentrated phase (Tg′) of the aqueous solution of DS in the presence of different components
was determined by a DSC 1 STARe System (Mettler Toledo, Greifensee, Switzerland). In brief, aliquots
of about 30–40 mg were cooled below the expected Tg′ at 1 K/min and kept at the temperature for 5 min.
Thereafter, samples were re-heated at 5 K/min to room temperature. To optimize the tablet formulation,
the effect of DS concentration and the presence of a surfactant (Span®80 or Tween®80) in different
concentrations on the tablet disaggregation time and IPEC size were evaluated. The composition of
tablets loaded with placebo IPECs is reported in Table 2.
Table 2. Tablet composition and its influence on hydrodynamic diameter (Dh) and zeta potential (ζ) of
placebo IPECs after disintegration.
Tablet
Code
Tablet Composition (%, w/w) Disintegration
Time (s)
Dh (nm) ζ (mV)
IPEC 1 IPEC 8 DS S80 T80
1 10% - 40.9 - - 6 149 ± 42 (54.9%) n.d.
2 10% - 81.8 - - n.d. * - -
3 - 10% 40.9 - - 11 136 ± 16 (95.6%) −26.6 ± 0.7
4 - 10% 81.8 - - n.d. * - -
5 10% - 40.9 0.01 - 20 141 ± 0 (97.8%) −26.6 ± 0.6
6 10% - 40.9 0.1 - 6 132 ± 8 (90.0%) −25.8 ± 0.1
7 10% - 40.9 0.5 - 26 145 ± 8 (98.4%) −26.0 ± 1.3
8 10% - 40.9 - 0.01 n.d. ** - -
9 10% - 40.9 - 0.1 n.d. ** - -
10 10% - 40.9 - 0.5 n.d. ** - -
11 - 10% 40.9 0.01 - 33 125 ± 10 (100%) −26.3 ± 1.9
12 - 10% 40.9 0.1 - 12 111 ± 9 (100%) −25.1 ± 3.0
13 - 10% 40.9 0.5 - 15 114 ± 12 (98.2%) −19.0 ± 2.1
14 - 10% 40.9 - 0.01 n.d. ** - -
15 - 10% 40.9 - 0.1 n.d. ** - -
16 - 10% 40.9 - 0.5 n.d. ** - -
17 20% - 40.9 0.5 - 26 165 ± 1 (100%) −46.9 ± 1.2
* Tablets presented an irregular surface due to the presence of bubbles. ** Tablets were sticky and, therefore, difficult
to handle.
Aliquots of 200 µL were poured into the cavity of PVC/OPA/Al/OPA/PVC laminate blister
(Catalent Pharma Solutions, Somerset, NJ, USA) and loaded into an Epsilon 2–6 laboratory scale
freeze-dryer (Martin Christ Freeze Dryers, Osterode, Germany). The samples were frozen at the rate
of 1 K/min to a minimum shelf temperature of −25 ◦C including two equilibration steps at 5 and
−5 ◦C for 15 min to achieve similar nucleation temperatures. After holding samples at −25 ◦C for
1 h, the chamber pressure was decreased to 0.120 mbar and the shelf temperature was increased to
−10 ◦C at 1 K/min to initiate the main drying. After 6 h of sublimation, the shelf temperature was
further increased to 40 ◦C at the rate of 1 K/min to initiate the secondary drying. The sublimation
phase was carried out over a 5 h period. Then, samples sealed under vacuum in glass vials were stored
at room temperature.
Tablets containing CP loaded IPECs were similarly prepared by weighing the exact amounts of
IPEC containing 120 µg drug per single unit.
The oral lyophilisates were characterized in terms of uniformity of mass and disintegration time
according to the Ph. Eur. 9th edition. After disintegrating one or two tablets in 10 mL of filtered
deionized water (Milli-Q™ Water system, Millipore Corporation, Vimodrone, Italy), particle size and
zeta potential of placebo and loaded IPECs were also measured.
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2.6. In Vitro Drug Release Test
The in vitro drug release test was performed according to a “sample-and-separate” method [10].
Considering the limited volumes of fluids in the buccal cavity, the in vitro release test was carried out
in oversaturation condition in order to better discriminate the different features of CP loaded IPECs.
Oral lyophilisates were placed in closed glass vials containing 20 mL deionized water and shaken
in a horizontal incubator at 50 strokes/min and 37 ± 0.5 ◦C. At each time point, a volume of 4 mL
medium was diluted with 1 mL acetonitrile, and the amount of CP released was quantified by the
high-performance liquid chromatography (HPLC) method reported in Section 2.7. The withdrawn
medium was replaced with equal volumes of deionized water.
2.7. HPLC Method
The CP content loaded into IPECs and released in the in vitro release test was assayed by
an HPLC method using HP1100 Chemstation (Agilent Technologies, Cernusco sul Naviglio, Italy).
Chromatographic conditions: column: Spherisorb ODS2, 4.6 mm × 150 mm, 3 µm (Waters, Vimodrone,
Italy); mobile phase: 50:50 (%v/v) acetonitrile:water; flow rate: 1.0 mL/min; wavelength: 240 nm;
injection volume: 20 µL. The drug concentrations were determined from standard curves ranging from
0.1 to 50 µg/mL [9].
3. Results
3.1. Characterization of Placebo IPECs
All IPECs obtained by mixing EPO and four types of carbomers differing in chemical composition,
molecular weight, or cross-linking were insoluble in water. To evaluate the possible interactions
between components, a physicochemical study was carried out by MDSC and FTIR spectroscopy.
According to the FTIR spectra, a new absorption band at 1560 cm−1 appeared in the IPEC with respect
to the raw materials, suggesting the formation of a new chemically individual compound (Figure 1).
This absorption band is diagnostic of the formation of ionic bonds between carboxyl groups of
Carbopol® and dimethylamino groups of EPO [16–19] and responsible for complex insolubilization.
MDSC data supported the formation of such interaction at a molecular level. EPO and carbomer are
both amorphous polymers with a characteristic Tg value (Table 3). After IPEC formation, a single value
of Tg was detected independently of the nature of anionic polyelectrolytes suggesting the absence of
microdomains of free copolymer. Moreover, the shift of Tg towards higher values with respect to the
starting polymers, suggests the formation of a stiffer material. The elementary analysis of IPEC after
washing revealed the presence of an excess of carbomer polymers in all samples (Table 3).
Regarding the particle size and particle size distribution, C10 and C2020, which provide
substantially more viscous solutions than the low molecular weight counterpart, allowed the formation
of nanoparticles (Table 4) and aggregates sizing about 5 µm. The percentage of this population of
large particles considerably increased decreasing the EPO content (Table 4). In contrast, the mixing of
NAA-1 and EPO led to the formation of nanoparticles of about 160 nm with a monomodal distribution
(Table 4).
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Figure 1. ATR-FTIR-spectra of C2020 and IPEC C2020/EPO (a); C71G and IPEC C71G/EPO (b); C10 
and IPEC C10/EPO (c); and NAA-1 and IPEC NAA-1/EPO (d). 
Table 3. MDSC data on raw materials and placebo IPECs. 
Samples Name Tg (°C) Composition (mol/mol) 
EPO 52.1  1.2 - 
C71G 129.5  1.2 - 
C2020 125.2  1.2 - 
C10 126.5  1.2 - 
NAA-1 131.3  1.5 - 
C71G/EPO 132.8  1.2 2.12:1 * 
C2020/EPO 133.5  1.2 1.73:1 * 
C10/EPO 134.8  1.1 2.11:1 * 
NAA-1/EPO 138.5  1.3 1.66:1 * 
* The composition of carbomer/EPO (mol/mol) IPECs is referred to the elementary analysis. 
Table 4. Main physical features, namely hydrodynamic diameter (Dh), zeta potential (ζ), and 
mucoadhesive properties of placebo IPECs. The value in the brackets refers to the percentage of the 
main population. 
IPEC 
Code 
Composition (%, w/w) 
ζ (mV) Dh (nm) MDF (kPa) WA (mJ) 
EPO NAA1 C10 C71G C2020 
1 67 33 - - - 14.7 ± 0.5 154 ± 9 (98.0%) 111 ± 10 2611 ± 413 
2 50 50 - - - −5.5 ± 2.5 154 ± 0 (97.6%) 100 ± 13 1848 ± 335 
3 33 67 - - - −16.0 ± 0.4 168 ± 4 (96.1%) 49 ± 6 741 ± 33 
4 67 - 33 - - 7.7 ± 1.0 222 ± 9 (94.1%) 85 ± 20 1462 ± 210 
5 50 - 50 - - −5.1 ± 0.9 158 ± 4 (96.2%) 103 ± 1 2154 ± 66 
6 33 - 67 - - −13.7 ± 0.5 149 ± 13 (52.7%) 45 ± 6 643 ± 57 
7 67 - - 33 - 4.3 ± 1.6 195 ± 12 (63.7%) 94 ± 17 1902 ± 322 
8 50 - - 50 - −47.8 ± 2.7 175 ± 17 (97.2%) 67 ± 31 1272 ± 448 
Figure 1. ATR-FTIR-spectra of C2020 and IPEC C2020/EPO (a); C71G and IPEC C71G/EPO (b);
C10 and IPEC C10/EPO (c); and NAA-1 and IPEC NAA-1/EPO (d).
Table 3. MDSC data on raw materials and placebo IPECs.
Samples Name Tg (◦C) Composition (mol/mol)
EPO 52.1 ± 1.2 -
C71G 129.5 ± 1.2 -
C2020 125.2 ± 1.2 -
C10 126.5 ± 1.2 -
NAA-1 131.3 ± 1.5 -
C71G/EPO 132.8 ± 1.2 2.12:1 *
C2020/EPO 133.5 ± 1.2 1.73:1 *
C10/EPO 134.8 ± 1.1 2.11:1 *
NAA-1/EPO 138.5 ± 1.3 1.66:1 *
* The composition of carbomer/EPO (mol/mol) IPECs is referred to the elementary analysis.
Table 4. Main physical features, namely hy ro ynamic diameter (Dh), zeta potential (ζ), and
mucoadhesiv pro erties of placebo s. The value in the brackets refers to the p rcentage of
the main populati
IPEC
Code
Composition (%, w/w)
ζ (mV) Dh (nm) MDF (kPa) WA (mJ)
EPO NAA1 C10 C71G C2020
1 67 33 - - - 14.7 ± 0.5 154 ± 9 (98.0%) 111 ± 10 2611 ± 413
2 50 50 - - - −5.5 ± 2.5 154 ± 0 (97.6%) 100 ± 13 1848 ± 335
3 33 67 - - - −16.0 ± 0.4 168 ± 4 (96.1%) 49 ± 6 741 ± 33
4 67 - 33 - - 7.7 ± 1.0 222 ± 9 (94.1%) 85 ± 20 1462 ± 210
5 50 - 0 - - −5.1 ± 0.9 158 ± 4 (96.2%) 103 ± 1 2154 ± 66
6 3 - 7 - - −13.7 ± 0.5 149 ± 13 (52.7%) 45 ± 6 643 ± 57
7 67 - - 33 - 4.3 ± 1.6 195 ± 12 (63.7%) 94 ± 17 1902 ± 322
8 50 - - 50 - −47.8 ± 2.7 175 ± 17 (97.2%) 67 ± 31 1272 ± 448
9 33 - - 67 - −28.8 ± 1.7 188 ± 9 (96.4%) 55 ± 9 1010 ± 95
10 67 - - - 33 −28.2 ± 4.0 166 ± 9 (90.0%) 89 ± 25 656 ± 51
11 50 - - - 50 −28.2 ± 3.5 192 ± 11 (83.3%) 43 ± 2 678 ± 25
12 33 - - - 67 −20.6 ± 1.8 225 ± 9 (71.9%) 57 ± 5 802 ± 109
Chitosan (positive control): MDF = 62 ± 10 kPa; WA = 1682 ± 162 mJ. Polyethylene (negative control):
MDF = 13 ± 1 kPa; WA = 407 ± 175 mJ.
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The evolution of zeta potential as a function of IPEC composition, which can be considered as
an indication of the degree of inter-particle interaction, is summarized in Table 4. As the carbomer
concentration increased from 33% to 67%, the zeta potential values shifted from 15 mV to a negative
value according to the extent and the type of anionic copolymer used for the preparation of IPEC.
This feature can be attributed to the presence of negatively charged carboxyl groups of Carbopol®,
which do not participate to the formation of ionic bonds with the positively charged dimethylamino
groups of EPO. Moreover, increasing the concentration of polyacrylate within the complex, the number
of such carboxylic groups also increases, which give a negative charge to the IPEC particles.
The mucoadhesive properties (in terms of both WA and MDF) of the complexes made with EPO
and different types of polyacrylate are reported in Table 4. All the IPEC compositions showed good
mucoadhesive properties, since both MDF and WA were statistically higher than those measured
using the negative control. As expected, the mucoadhesive performances of IPECs were influenced
by the ratio between the polymers. The higher the EPO amount in each IPEC series, the higher the
mucoadhesive properties. Indeed, when EPO concentration was 67%, the change of the IPEC charge
from negative to positive values, as estimated by the zeta potential, allows the dimethylamino groups
of EPO to interact by ionic bonds with the negatively charged ionized groups of sialic acid at the
terminus of mucin subunits. The lower values of MDF, associated to a more negative of zeta potential,
might be the result of greater repulsion between negative charges of mucin and IPECs.
These results indicate that mucoadhesion of IPECs made of C10, C71G, and NAA-1 are mainly
attributed to the formation of electrostatic interactions. On the other hand, such mechanism of
interaction cannot help to explain the behaviour of IPEC made with C2020, for which a less negative
zeta potential in comparison with the raw polymer (C2020) was related to weaker mucoadhesion.
Indeed, beyond the zeta potential values, other features of polymers (e.g., chemical composition and
structure) can influence their ability to adhere to mucosa [20]. In the case of raw polymers, the more
negative zeta potential may establish a better uncoiling to interpenetrate with oligosaccharide mucin
chains. The mucoadhesion of C2020/EPO IPEC can be attributed by the formation of hydrogen bonds
between carboxyl groups of Carbopol® and mucin, since mucoadhesion of polymers containing weak
anionic carboxyl, such as polyacrylic acid (Carbopol®), is often related to the formation of hydrogen
bonds with mucin [21].
3.2. Oral Lyophilisates Containing Placebo IPEC
The physico-chemical characterization of placebo IPECs permitted to consider two materials
worth of further characterization. In particular, C71G/EPO (50:50) and NAA-1/EPO (33:67) were
chosen based on the zeta potential value (Table 4) to evaluate how the superficial properties
can affect the formulation of oral lyophilisates and resuspendibility. In addition, IPEC made of
NAA-1/EPO (33:67) is characterized by the highest rates of mucoadhesion (Table 4), which can
also influence the properties of the final dosage form. To obtain oral lyophilisates with suitable
characteristics, it is necessary to tune up both the formulation and the lyophilization parameters.
Of fundamental importance to preserve IPEC nano-size during the lyophilization process is the
selection of the type and concentration of lyoprotectants and steric stabilizers. The “vitrification
hypothesis” suggests the possible role of lyoprotectants during freezing: saccharides form a glassy
system, known also as cryo-concentrated phase, where nanoparticles are immobilized and preserved
from the ice crystals [22]. Besides lyoprotectants, steric stabilizers can improve the nanoparticles
stability during the lyophilization according to the “water replacement theory”. This theory suggests
that the hydrogen bonds between water and nanoparticles are replaced by interactions occurring
onto nanoparticles surface with the adsorbed steric stabilizer, thus avoiding particle aggregation
or fusion [23]. Steric stabilizers are generally polymers and surfactants, such as polysorbates and
poly(vinyl alcohol).
Once both lyoprotectants and steric stabilizers are defined, an adequate lyophilization cycle is
designed based on the Tg′ and the Tc. Indeed, the formulation is required to be cooled below its Tg′
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to assure the complete solidification [24] and Tc, which is the maximum allowable temperature of
product during primary drying, to avoid the collapse [25]. Thermal analysis indicated that the Tg′ of a
DS solution at 40% was −21.81 ± 0.3 ◦C without being significantly affected by the presence of the
surfactant (Tg′ = −20.56 ± 0.25 ◦C); meanwhile the dispersion of 10% IPEC caused a slight increase
in Tg′ value to −19.10 ± 0.04 ◦C, as exemplified in Figure 2. Hence, the samples were frozen at the
temperature of −25 ◦C, considering a safety product margin of about 2 ◦C [21].
The final concentrations of the additives (i.e., lyoprotectants and steric stabilizers) in the
formulations containing IPEC are reported in Table 2. All freeze-dried tablets loaded with IPEC
presented as a white spongy texture. The tablets occupied the same volume of the original frozen mass
and no shrinkage or cake collapse was observed, demonstrating that the process parameters yielded
good lyophilisates.
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Tablets obtained by the DS solution at the highest concentration presented a very irregular surface
due to the presence of bubble after filling the blisters. Decreasing the DS concentration to about 40%,
visually acceptable tablets were obtained and, therefore, they were disintegrated in water in order to
characterize IPECs in terms of particle size and PDI. The presence of a steric stabilizer was essential
during lyophilization since DS as such was not able to avoid the formation of large and irreversible
aggregates (Table 2). However, sticky tablets, difficult to handle, were obtained by using Tween®80
independently of its concentration and, therefore, discarded from further evaluation. Span®80 was
effective as a steric stabilizer as a function of its concentration since only the formulation containing
DS in combination with 0.5% of Span®80 preserved the IPEC size upon lyophilization (Table 2).
Additionally, the ratio between the cryoprotectant and IPEC influenced the freeze-drying process,
since at 20% IPEC loading the resuspended particles exhibited a monomodal distribution with a low
size heterogeneity (PDI ~0.15). This evidence agreed with the results on the lyopresevation effect of
threalose on diblock and triblock poly(lactic acid)-poly(ethylene oxide) copolymer nanoparticles—the
lyoprotective efficiency increased at higher nanoparticles concentration [26].
After lyophilization and redispersion, IPECs shifted their characteristic surface charge from about
15 to −25 mV (Table 2). This variation can be the result of a “masking-effect” due to the adsorption
of maltodextrin on the positive surface of IPEC. This result is in line with literature data since the
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entrapment of nanoparticles in some polymers usually modifies the zeta potential because the coating
layers shield the surface charge and move the shear plane out wards from the particle surface [27–29].
According to the obtained results, the optimal composition was 20%, IPEC NAA-1/EPO (33:67),
40.9% DS, and 0.5% Span®80 since the resulting oral lyophilisates have the required disintegration time
(<30 s) and after disintegration test IPEC particles had a monomodal distribution without aggregates.
Thus, this composition was selected to produce oral lyophilisates loaded with CP.
3.3. CP Loaded IPECs
The effect of different CP loading on the main features of IPEC made of NAA-1 and EPO in the
ratio 33:67 was evaluated. The loading procedure gave a high encapsulation efficiency in all considered
ratios (Table 5).
Table 5. Characterization of clobetasol propionate (CP) loaded into IPEC formed by NAA-1 and EPO
in the ratio 33:67 %.
Composition
CP Content (%)
Dh (nm) ζ (mV) MDF (kPa) WA (mJ)
Theoretic Actual
CP-IPEC 50:50 50 53.2 ± 0.3 401 ± 295 −11.3 ± 2.1 30 ± 6 2530 ± 58
CP-IPEC 60:40 60 56.1 ± 1.4 435 ± 197 −9.0 ± 1.2 22 ± 5 2988 ± 110
CP-IPEC 70:30 70 62.1 ± 5.3 431 ± 119 −10.8 ± 1.2 18 ± 2 2550 ± 27
CP-IPEC 80:20 80 79.4 ± 0.2 560 ± 116 6.8 ± 2.8 16 ± 2 1400 ± 26
CP-IPEC 90:10 90 88.5 ± 12.6 416 ± 6 3.8 ± 2.2 15 ± 1 820 ± 19
The FTIR spectra of CP loaded IPECs revealed that no interactions occurred independently on
their ratio (Figure 3).
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Figure 3. ATR-FTIR-spectra of raw material CP (panel (a)) and CP loaded IPECs in the following ratio:
(panel (a)) 9:1, 8:2; (panel (b)) 7:3, 6:4, 5:5.
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This result is consistent with the MDSC data as the endothermic event attributed to CP melting
was observed in all samples and it increased the drug content accordingly (Figure 4). Independently of
the drug content, IPEC dimension increased from around 160 to 450 nm (Table 5). This behavior can be
due to the presence of aggregates since the drug loading caused a shift of zeta potential value in the
range of instability (Table 5).
As far as the mucoadhesion is concerned, the drug loading led to a decrease in the MDF values of
IPECs (Table 5), at a higher extent with increasing CP content. As a matter of fact, the values obtained
for CP content higher than 70% (i.e., formulations CP-IPEC 80:20 and 90:10) resulted not significantly
different from the negative control. On the other hand, for all the tested formulations, WA was higher
than the negative control and, for those with low CP content (i.e., formulations CP-IPEC 50:50, 60:40,
and 70:30), it was of the same order of magnitude of the corresponding placebo IPECs.
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In the case of drug loaded IPECs, the decrease in MDF, not concurrent with a decrease in WA,
could be due to an increase of the viscous modulus of the hydrated interpolymeric complex/mucin
mixture. As a matter of fact, the last phase during the separation of the drug loaded IPECs showed
a resistance to the detachment in terms of elongation and time, higher than the placebo. Indeed,
the mucin compact was not totally detached from IPEC compact due to the formation of visually
observed fibrils. Oral lyophilisates were obtained by dispersing an appropriate amount of CP loaded
IPECs in the DS solution in order to have a drug content of 120 µg/unit. The final composition is
reported in Table 6. After freeze-drying all tablets appeared as elegant solids without defects or sign of
collapse, easy to remove from blister and to handle. The disintegration time of all oral lyophilisates
was less than 30 s and no aggregates were detected confirming suitability of components to stabilize
IPECs during the lyophilization process (Table 6). The zeta potential values of all resuspended IPECs
shifted towards the neutrality probably because the excipients remained adsorbed on the IPEC surface.
Table 6. Composition of oral lyophilisates containing CP loaded IPECs formed by NAA-1 and EPO in
the ratio 33:67 %. The amount of IPEC was defined in order to have 120 µg drug per unit. The main
features of CP loaded IPECs after disintegration were evaluated in terms of particle size (Dh) and
zeta-potential (ζ).
Formulation
Tablet Composition (%w/w)
Dh
Disintegration
Composition IPEC an®80 S Ti e (s) (n ) ζ (mV)
1 CP-I EC 50:50 0.29 .20 0 2 9 122 .6%) <30 3 ± 69 1.08 0.1
2 CP-IPEC 60:40 0.24 1.21 98.55 419 ± 81 <30 363 ± 122 −0.99 ± 1.25
3 CP-IPEC 70:30 0.21 1.21 98.59 306 ± 198 <30 350 ± 87 −4.42 ± 0.46
4 CP-I EC 80:20 0.18 .21 .61 369 78 <30 448 ± 122 −2.90 ± 1.64
5 CP-IPEC 90:10 0.16 1.21 98.63 518 ± 88 <30 356 ± 70 3.27 ± 0.60
The dissolution profiles showed that the CP encapsulation into IPEC improved its apparent
solubility as a function of the loaded drug amount (Figure 5). Indeed, the CP-IPEC ratio of 50:50
exhibited the highest supersaturation degree, which was conversely unstable, since after 120 min the
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concentration of CP in the dissolution medium was superimposable to that of CP solubility. On the
other hand, at the CP-IPEC ratio of 90:10 (Formulation 5) the steady state was reached in about 2 h.
Based on these observations, it can be assumed that IPEC not only controlled the drug release rate,
but also favored the stabilization of the supersaturated system. Indeed, when the CP amount ranged
from 80% to 60% (Formulations 2–4, Table 6), a stable supersatured solution was obtained over the
entire considered period of time.
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Figure 5. In vitro dissolution profile of CP from oral lyophilisates containing CP-IPEC w/w: 9:1 (90:10),
7:3 (70:30), and 5:5 (50:50) under oversaturation conditions. The dotted line corresponds to the CP
solubility at the saturation.
4. Conclusions
A new drug delivery system obtained combining the colloidal and mucoadhesive properties of
IPEC formed by Carbopol® and EPO, was proposed to treat buccal pathologies. In particular, the
ability to interact with mucin was attributed to the IPEC structural features, namely the presence
of free dimethylamino groups of EPO or carboxylate groups of Carbopol®. Indeed, the higher the
mucoadhesion, the higher the excess of unbalanced charge in IPEC. Regarding oral lyophilisates,
the use of maltodextrin DE 38 and Span®80 preserved the IPEC size during the thermal stress so that
it was possible to reconstitute the original nanosuspension upon contact with water in few seconds.
Moreover, this approach allowed to improve the CP apparent solubility thanks to the formation of a
stable supersaturated system.
Hence, the overall data suggest that this dosage form could be advantageously exploited in drug
delivery systems as demonstrated in the case of clobetasol propionate.
The performed work also permitted us to withdraw general information on the design of oral
lyophilisates loaded with nanosized particles. Scheme 1 detained the general approach, underling the
selection criteria of each phase and the most important variables to be considered.
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